Table 1. Information for the patients’ samples used in this study.

AD, Alzheimer’s disease; FTLD_tau, frontotemporal lobar degeneration with tau pathology; LBD, Lewy body dementia; PMI, postmortem interval; M, male; F, female; NIA-AA, National Institute on Aging–Alzheimer's Association.

	Control	Preclinical AD	AD	FTLD_tau	LBD
Description	Healthy individuals/normal controls–frontal cortex	Asymptomatic/preclinical AD with mild AD pathology–frontal cortex	End-stage AD	FTLD_tau–frontal cortex	LBD–frontal cortex (with minimal neurodegeneration)
n	10	9	14	10	10
Age at death (means ± SD)	69.3 ± 9.7	81.4 ± 9.5	69.7 ± 11.0	66.4 ± 11.9	71.3 ± 9.3
Sex	5 (M) and 5 (F)	5 (M) and 4 (F)	8 (M) and 6 (F)	7 (M) and 3 (F)	6 (M) and 4 (F)
Race	7 (white) and 3 (Black)	8 (white) and 1 (Black)	13 (white) and 1 (Black)	9 (white) and 1 (Hispanic)	10 (white)
PMI	8.2 ± 3.5	8.4 ± 5.3	8.2 ± 4.8	5.8 ± 4.4	13.7 ± 5.3
Diagnosis	The normal control group was composed of individuals with no history of neurologic disease and no obvious neurodegenerative pathology at autopsy.	The asymptomatic AD group was composed of individuals with normal cognition who exhibit obvious AD pathology at death (ABC scores of “low” and “intermediate”) (49).	“ABC” scores were determined per NIA-AA guidelines (49)	FTLD_tau was assessed according to consensus guidelines (50, 51).	The diagnosis of Lewy body disease was established using consensus criteria (51, 52).